Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis

Abstract

New treatments continue to be developed for psoriasis. In this review, we aim to summarize the results of the major published studies on biologic and small molecule drugs for the treatment of psoriasis. We emphasize the safety, efficacy, and tolerability of these treatment options. A review of the MEDLINE database was conducted for each class of medication. Randomized controlled trials were identified for each medication; data on efficacy, safety, and tolerability were reviewed. Biologic and small molecule treatment options are more effective than placebo, although there were few head-to-head trials to assess relative efficacy between biologics and small molecule treatments. These drugs offer favorable safety profiles with only rare serious adverse events reported. Biologic and small molecule drugs offer diverse therapeutic regimens, particularly in patients with recalcitrant disease.

Gold lotion from citrus peel extract ameliorates imiquimod‐induced psoriasis‐like dermatitis in murine

“…49 Thus, small molecule inhibitors or monoclonal antibodies targeting these cytokines have been used in the clinical treatment of both skin and joint manifestations of psoriasis. 50,51 In this study, we observed that oral administration of GL attenuated TNF-, IL-6, IL-17A/F, IL-22, and IL-23 production in skin lesions induced by IMQ (Fig. 3).…”

“…It is known that production of TNF‐α, IL‐6, IL‐17A/F, IL‐22, and IL‐23 is elevated in both the skin and synovium of psoriatic patients . Thus, small molecule inhibitors or monoclonal antibodies targeting these cytokines have been used in the clinical treatment of both skin and joint manifestations of psoriasis . In this study, we observed that oral administration of GL attenuated TNF‐α, IL‐6, IL‐17A/F, IL‐22, and IL‐23 production in skin lesions induced by IMQ (Fig.…”

Within Our Skin

“…In this issue, Turberville et al . summarize recent advances in the pharmacological treatment of psoriasis . Generally considered an autoimmune disease, psoriasis is a chronic skin condition that affects 2–3% of the population.…”

“…In this issue, Turberville et al summarize recent advances in the pharmacological treatment of psoriasis. 10 Generally considered an autoimmune disease, psoriasis is a chronic skin condition that affects 2-3% of the population. Hyperproliferation of keratinocytes, resulting in scaly skin and plaque formation, causes a disruption of the skin barrier which can be severely painful, debilitating, and prone to infections.…”

Full-Length Transcriptome Sequencing Analysis of Differentially Expressed Genes and Pathways After Treatment of Psoriasis With Oxymatrine

“…These agents are associated with an increased risk of infections, though mostly tend to be mild infections. The use of biological agents has certain contraindications and the risks of infection along with long-term usage may potentially lead to tumorigenesis in patients with active pulmonary tuberculosis, advanced congestive heart failure, hepatitis B infection, or demyelination diseases, including multiple sclerosis (Turbeville et al, 2017). Drug resistance and disease recurrence along with unintentional disruption of other pathways are a few shortcomings involved with the usage of biological agents (Reich et al, 2005).…”